Prostate Cancer - Newer Antiandrogens and Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population; New Report Launched

This report details current unmet need, changing regulatory requirement, reimbursement challenges & market dynamics of Prostate Cancer drugs.  Report mention pipeline Antiandrogens, late stage prostate cancer pipeline drugs/new Mechanism of action & major companies developing Prostate cancer drugs.  It also provides insight on clinical development strategy of combination pipeline/marketed drugs & therapeutic competitive landscape to find treatment paradigm fit & market potential of new drugs for treatment of Prostate Cancer.

Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high.  This has expanded WW market size of Prostate cancer drugs to $7b in 2016 from $2.5b in 2011.  Now nmCRPC, HSPC and Xtandi/Zytiga resistance population are the markets where in new pipeline drugs are under development.

Reported PhII clinical data of Xtandi, ARN-509 and ODM-201 in nmCRPC when indirectly compared demonstrate the bar is high for ARN-509 to compete against Xtandi in nmCRPC market and while ODM-201 is few years behind in clinical development.  While in mHSPC reported clinical results of STAMPEDE study opens door for docetaxel combination approach as standard of care in first line setting.

Around 8 plus drugs are in PhIII development for Prostate cancer treatment and 26 plus drugs are in PhII development (21 small molecules) - success of a few (ARN-509, ODM-201, AZD 5363, GX301) in coming years will expand nmCRPC ($3.5be), mHSPC market  ($1be) and Xtandi/Zytiga resistant population ($1be) market by 2023.  Longer duration of therapy and high prevalence makes earlier setting market more attractive and bigger for newer options than the late stage if they succeed.

For drugs targeting through androgen pathway - Now trials and clinical development is underway for second and third generation androgen receptor inhibitors (ARN-509, ODM-201, ODM-204, EPI-506, VT-464, TAS-3681 and DR103).  While androgen synthesis inhibitors still needs a proof of concept in clinic due to failure of TAK-700 & TOK-001.  Expected data from VT-464 (Apr 2017) & ASN-001 will be important to watch to taste the success for this class.  Androgen receptor degrader is another MoA in development from a decade and success of in clinic compound GTX-758 (Data expected anytime from now as study completed in March 2016- less likely to succeed) will decide the proof of concept.

Other than pipeline drugs targeting androgen pathway, NCE targeting AKT pathway (AZD5363, Ipatasertib) appears to be more promising to succeed in late stage, while drugs acting through PARP inhibition (Olaparib, Niraparib) still needs a taste of success. Other interesting pipeline asset is LHRH agonist LMIS 50 mg, which is designed to overcome the drawbacks of the commercial depot products containing GnRH agonists by using a proprietary delivery system. 

Also 6 therapeutic vaccines are in clinical development to treat prostate cancer. Recently launched PD-L1 IO therapy has increased hope of treating cancer in much safer way.  Current ongoing studies of late stage IO mab are in Ph I/II clinical development and would be able to answer of PTEN hypothesis for role of PD-1, PD-L1 inhibitor to treat prostate cancer in coming years.

Resistant development is another challenge with long term use of   Xtandi/Zytiga and needs to be addressed by pipeline second/third generation Antiandrogens/ combination approach with IO/PARP/AKT inhibitors to treat mCRPC.   Increase in pricing pressure in developed market again put inference on Combination approach unless the advantage is significant and improve the Q0L in earlier setting.  Due to that, drugs targeting adjuvant setting has high bar to deliver (Atezolizumab, GX301, Mipsagargin and Olaparib) in the clinical development to add significant value.

Spanning over 200 pages “Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population” report covers Executive Summary, Prostate Cancer, Pipeline Antiandrogens, Targeting Xtandi and Zytiga Non Responder and Resistant population, Combination of drugs with IO therapy, New pipeline drugs. This report Covered Companies few are - Pfizer, Medivation, Astellas, Valeant pharmaceuticals, Turing pharmaceuticals, Abbott, Johnson & Johnson, Tokai pharmaceuticals, Bayer pharmaceuticals, AstraZeneca, Teva pharmaceuticals, Mylan, Bind therapeutics, NanoString Technologies, Zenith Technologies, Actavis, Apotex, Par  pharmaceuticals, Citron pharma, Dr. Reddy’s Laboratories, Sun pharma, Wockhardt, Amneal pharmaceuticals.

For more information Visit at: http://mrr.cm/3Cw

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Radiotherapy Market by Products Market Outlook 2022; New Report Launched

With increasing economic burden associated with proliferation of cancer worldwide, radiation therapy has become a boon for the patients. Technological advancement in the field facilitates more precise and noninvasive therapies. The report “Global Radiotherapy Market by Products (Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy)- Market Outlook 2022” provides an in-depth analysis of global radiotherapy market focusing on external beam radiation therapy products such as Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy. Market analysis of aforementioned radiotherapy products has been forecast for the period 2017-22.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level.

The report has been segmented as following:-

Market Segmentation by Products

• Proton Therapy
• Linear Accelerator (LINAC)
• CyberKnife
• Gamma Knife
• TomoTherapy

Key Vendors

• Varian Medical Systems
• Elekta AB
• Accuray Inc.

Spanning over 57 pages, 4 Tables and 42 Figures “Global Radiotherapy Market by Products (Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy)- Market Outlook 2022” report covers Executive Summary, Research Methodology, Radiotherapy Market, Global Radiotherapy Market Segmentation by Products, Global Radiotherapy Market Dynamics, Competitive Landscape, Company Profiles. This report Covered Companies - Varian Medical Systems, Elekta AB, Accuray Inc.

For more information Visit at: http://mrr.cm/3CN

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Proton Therapy Market Outlook 2021; New Report Launched

The report “Global Proton Therapy Market Outlook 2021” provides an in-depth analysis of global proton therapy treatment market with focus on major regional market such as North America, Europe and Asia Pacific. North America is the world’s largest proton therapy market with high predominance in the US. In Europe, Germany and the UK are major markets. The proton therapy systems market has been segmented into pencil beam scanning systems, uniform scanning systems and passive scattering systems on the basis of type of system. Out of these, pencil beam scanning being most precise form of proton therapy enjoys highest popularity.

Growth of the global proton therapy industry is driven by rise in cancer incidences, especially prostate cancer. Rising prevalence of chronic diseases in ageing population globally; and minimal invasiveness associated with use of proton therapy. However, major industry restraints include stringent regulations, high installation costs and reimbursement being limited to few uncommon cancer types. Global proton therapy industry is highly consolidated with three major players – IBA Proton Therapy Inc, Varian Medical Systems and Hitachi Limited dominating the market. These players have been profiled in the report.

Market Segmentation by Region

• North America
• The US
• Asia Pacific
• Europe

Key Vendors

• IBA Proton Therapy Inc
• Varian Medical Systems
• Hitachi Ltd

Spanning over 62 pages, 13 Tables and 42 Figures “Global Proton Therapy Market Outlook 2021” report covers Executive Summary, Research Methodology, Proton Therapy, Proton Therapy Market Analysis, Global Proton Therapy Market: Regional Analysis, Proton Therapy Market Dynamics, Competitive Landscape, Company Profiles. This report Covered Companies - IBA Proton Therapy Inc, Hitachi Ltd, Varian Medical Systems.

For more information Visit at: http://mrr.cm/3CG

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Molecular Diagnostics Companies Market Research Report: The Top 600 In-Vitro Diagnostics Companies Worldwide; New Report Launched

Did you know?

• Transasia Bio-Medicals is India’s largest in-vitro diagnostics company.
• Diachel SA is the leading independent in-vitro diagnostics distributor in Greece, offering complete laboratory solutions, from sales to after-sales support and service.
• Una Health Ltd., the fastest growing diagnostics distributor in the United Kingdom, specialises in bringing innovative point-of-care devices to the market.
• Abbott Diagnostics is #1 in immunoassay and blood screening worldwide.
• OraSure Technologies, Inc. has 327 employees.
• Marcel van Kasteel is Vice President & General Manager at Philips Handheld Diagnostics.
• OvaGene is unlike any other molecular diagnostics company; their only focus in on women's pelvic cancers and related conditions.
• In June, 2016, GenMark achieved the CE Mark for its ePlex sample-to-answer multiplex molecular diagnostics System and ePlex Respiratory Pathogen (RP) Panel.
• Trinity Biotech plc has point-of-care revenues of $20.0 million.
• Genetic Signatures is seeking to enter the U.S. market with strategic customer relationships and partnerships.
• Micronics, Inc., a leading developer of near-patient point-of-care in vitro diagnostics products, is a wholly owned subsidiary of Sony Corporation of America.
• In October, 2016, British distributor, YouMed Ltd. announced an agreement with Mobidiag Ltd., a Finnish molecular diagnostics company, to became an agent for Mobidiag’s Amplidiag® in-vitro diagnostic tests and compatible system for the detection of gastrointestinal infections.

These are just a tiny sample of the 1,000's of facts to be found in ‘The Top 600 In-Vitro Diagnostics Companies Worldwide’.

This unique and comprehensive report (1,051 pages) identifies and profiles the leading 600 manufacturers and distributors of core laboratory, point-of-care and molecular diagnostics.They are located right across the globe from the United States and Europe to India and China.

Profile information for companies in ‘The Top 600 In-Vitro Diagnostics Companies Worldwide’ includes:

• Company Contact Information - Address, Telephone and Fax Numbers, Email and Website Addresses
• Key Company Decision Makers - From CEO and Main Board, to Key Senior Managers
• Specialised fields such as Company Description, Products, Manufacturers Represented, Clinical Specialties/Diseases, Countries Served, Year Established, Number of Employees, Revenue ($U.S. million), Parent Company, Location Status, Ownership, Stock Exchange/Ticker Symbol

Report Target Market:

1) IVD Manufacturers

2) IVD Suppliers

3) IVD Distributors

4. IVD Industry Associations

Note: Most people will be aware of some of the major IVD companies such as Abacus ALS, Axon Lab, EKF Diagnostics, Nova Biomedical, Onkogen Diagnostik and QIAGEN but this major new report looks at all 600 of the top IVD companies worldwide - companies like:

- Sekisui Diagnostics - Sekisui Diagnostics is a diverse company with broad product lines, a global sales and distribution network, extensive product development capabilities, state of the art manufacturing facilities and deep diagnostics expertise. Over 1.5 billion tests are performed each year using the Company’s clinical chemistry products. Sekisui Diagnostics is headquartered in Lexington, MA, United States, has annual revenue of $175.0 million and over 525 employees worldwide. The Company is led by Bob Schruender, President and Chief Operating Officer. Sekisui Diagnostics is a member of AdvaMedDX.

- Inter Medico - Founded in 1979 by Dan Lichtman, President, Inter Medico is the largest Canadian-owned distributor of in-vitro diagnostics. The Company has strategic alliances with world-class manufacturers including Abbott Molecular, Biokit, Cepheid, Dako, Grifols, Helena Laboratories, Immunodiagnostic Systems, Inova Diagnostics, Siemens Healthcare and Trinity Biotech. Inter Medico’s products can be found in Canadian hospitals, reference laboratories, universities, and the biopharmaceutical industry.

- Chembio Diagnostic Systems, Inc. - Headquartered in Medford, New York, United States, Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care diagnostic tests and technology for the detection of infectious diseases. The Company’s Dual Path Platform (DPP®) technology is providing it with a significant pipeline of business opportunities for the development and manufacture of new products. On November 3, 2015 Chembio announced plans to commercialise multiple combination DPP® Malaria Assays to identify plasmodium falciparum and other plasmodium infections. Founded in 1985, Chembio had revenues of $U.S. 27.6 million in 2014. It currently has 166 employees and is led by John J. Sperzel, Chief Executive Officer.

- Triolab AS - Founded in 1991, Danish company Triolab AS offers an extensive product range from point-of-care testing to full automation of clinical laboratories in the fields of coagulation, haematology, clinical chemistry, transfusion and transplantation diagnostics, molecular diagnostics and microbiology. The Company represents many leading diagnostics products manufacturers and has customers in all healthcare segments, from small clinical laboratories to large laboratory centres and hospital departments Triolab is part of the Swedish Addtech Group and has sister companies in Finland, Norway and Sweden. Together they are one of the leading diagnostic suppliers in the Nordic area. Triolab is led by Finn Ulbæk Andersen, Managing Director.

- Biocartis Group NV - Headquartered in Mechelen, Belgium, Biocartis Group NV is an innovative commercial stage, molecular diagnostics company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis Group NV is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases, the fastest and largest growing segments of the $U.S. 5.0 billion MDx market. The Company employs 300 people and had revenue of $U.S. 16.7 million in 2015. Biocartis Group NV has been listed on Euronext Brussels (BCART) since April 2015 and is led by Rudi Pauwels, Chief Executive Officer.

- Celtic Molecular Diagnostics (Pty) Ltd. - Founded in 2003, Celtic Molecular Diagnostics (Pty) Ltd. is a young, dynamic company providing high quality, innovative and affordable products to scientists in molecular research and diagnostic laboratories throughout Southern Africa. The Company aims to be a leading supplier of reagents and instrumentation in Southern Africa, through partnerships with prestigious manufacturers e.g. altona Diagnostics GmbH, Amoy Diagnostics Co., Ltd., Asuragen Inc., Invivoscribe, MRC-Holland, Primerdesign Ltd., Qnostics Ltd. and Sacace Biotechnologies Srl.. Celtic Molecular Diagnostics (Pty) Ltd. is led by Dermot Cox, Managing Director.

Publisher is one of the world’s leading companies in life sciences publishing. It has a large portfolio of best-selling reports spanning diagnostics, pharmaceuticals, biotechnology and medical devices. It’s customers include most of the world’s major companies in these sectors e.g. Abbott Laboratories, ACON Laboratories, Alcon, Allergan, Aurobindo Pharma, Axis-Shield, Baxter, Bayer, B. Braun, BD, Biomerieux, Biomet, Boehringer Ingelheim, CareFusion, Covance, Covidien, C.R. Bard, Edwards Lifesciences, Fresenius, GE Healthcare, Genzyme, HemoCue, Intuitive Surgical, Ipsen, Johnson & Johnson, Medtronic, Merit Medical Systems, Millipore, Mölnlycke Health Care, Novartis, Paul Hartmann, Philips Medical, Qiagen, Siemens Healthcare, Smith & Nephew, Synthes, Teleflex, Teva, Zentiva etc.. Publisher also counts many multinational financial services, law and management consulting firms such as Bain & Company, McKinsey & Company and The Boston Consulting Group among its customers.

Publisher currently has customers in some forty countries across the globe e.g. Austria, Australia, Belgium, Brazil, Canada, Cyprus, Czech Republic, Denmark, France, Germany, Finland, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Luxembourg, Mauritius, Netherlands, Pakistan, Peru, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, and the United States.

Publisher' reports help you make informed decisions about the markets and organisations that affect your business.

• Learn more about your target markets and target companies
• Top level research on all the major players in a market
• See which organisations dominate your major markets
• Get detailed information on particular organisations

For more information Visit at: http://mrr.cm/3C3

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Global Medical Robotic Systems Market - Focus on Orthopedic Robotic Surgery Outlook 2021; New Report Launched

The report “Global Medical Robotic Systems Market - Focus on Orthopedic Robotic Surgery Market Outlook 2021” provides an in-depth analysis of global medical robotic systems market and robotic surgery market with focus on orthopedics segment. The industry has worldwide been acknowledged as a technological field with major breakthrough expected in upcoming years.

Growth of the industry is attributed to use of robotic surgery for treatment of various chronic diseases such as arthritis, cancer, respiratory diseases and cardiovascular diseases. These diseases are more prevalent in ageing population. Hence growing incidence of chronic diseases, ageing population, high precision rate associated with surgical robots and rise in demand of robotic surgery in emerging markets are seen as major growth drivers of the industry. However, factors such as high regulatory risk, medical device recalls, lack of trained workforce and high-entry level costs are major restraints.

Global Medical Robotics market is dominated by Intutive Surgical Inc., Stryker Corporation, Accuray Inc., Hansen Medical, Inc., among others. Intutive Surgical Inc., Stryker Corporation and Accuray Inc. are profiled herein based on attributes such as business overview, product segments, financial and business strategies.

The report “Global Medical Robotic Systems Market - Focus on Orthopedic Robotic Surgery Market Outlook 2021” provides an in-depth analysis of global medical robotic systems market and robotic surgery market with focus on orthopedics segment. The industry has worldwide been acknowledged as a technological field with major breakthrough expected in upcoming years.

Growth of the industry is attributed to use of robotic surgery for treatment of various chronic diseases such as arthritis, cancer, respiratory diseases and cardiovascular diseases. These diseases are more prevalent in ageing population. Hence growing incidence of chronic diseases, ageing population, high precision rate associated with surgical robots and rise in demand of robotic surgery in emerging markets are seen as major growth drivers of the industry. However, factors such as high regulatory risk, medical device recalls, lack of trained workforce and high-entry level costs are major restraints.

Global Medical Robotics market is dominated by Intutive Surgical Inc., Stryker Corporation, Accuray Inc., Hansen Medical, Inc., among others. Intutive Surgical Inc., Stryker Corporation and Accuray Inc. are profiled herein based on attributes such as business overview, product segments, financial and business strategies.

Spanning over 66 pages, 9 Tables and 32 Figures “Global Medical Robotic Systems Market - Focus on Orthopedic Robotic Surgery Market Outlook 2021” report covers Executive Summary, Research Methodology, Medical Robotic Systems, Robotic Surgery, Orthopedic Robotics Surgery Market, da Vinci Surgical Systems, Market Dynamics, Competitive Landscape, Company Profiles. This report Covered Companies - Intutive Surgical Inc., Stryker Corporation and Accuray Inc.

For more information Visit at: http://mrr.cm/3Cx

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Healthcare Exoskeletons market is expected value of over $2.49 billion during 2017 - 2023; Finds New Report

During 2017-2023, global demand for healthcare exoskeletons is poised to a cumulative market value of over $2.49 billion including direct sales, renting, leasing, insurance reimbursement and other revenue sources. In terms of unit shipment from direct sales, the global total market over 2017-2023 is expected to reach 27,180 units, representing an exponential CAGR over the forecast years.

Global Healthcare Exoskeletons Market 2016-2023: Structure Analysis, Trend Outlook and Business Strategy is based on a comprehensive research of the healthcare exoskeletons market by analyzing the entire global market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

In-depth qualitative analyses include identification and investigation of market structure, growth drivers, restraints and challenges, emerging product trends & market opportunities, Porter’s Fiver Forces, partnership and fundraising landscape. Moreover, risks associated with investing in global healthcare exoskeletons market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders manage and minimize the risks, develop appropriate business models, and make wise decisions.

The report quantifies global healthcare exoskeletons market in every aspect of the classification from perspectives of application, mobility type, product function, power technology and region.

Based on application, the global market is segmented into the following sections with annual revenue data available for each section over 2014-2023:

• Rehabilitation
• Mobility Aid
• Other Applications

On basis of mobility type, the global market is studied in the following segments with annual revenue data provided for each sub-segment covering 2014-2023:

• Mobile Exoskeletons
• Stationary Exoskeletons
• Tethered Exoskeletons

On basis of product function, the global market is studied in the following segments with annual revenue available for each sub-segment covering 2014-2023:

• Upper Body Exoskeletons
• Lower Body Exoskeletons

On basis of power technology, the global market is segmented into the following sections with annual revenue forecast for each section covering 2014-2023:

• Active Exoskeletons (by power type, this section is further classified into Electric Actuator, Pneumatic Actuator, Hydraulic Actuator, Fuel Cell, and Others)
• Passive Exoskeletons

Geographically, the following five regions together with the listed leading national markets are fully investigated:

• APAC (China, Japan, South Korea, Australia, India, and Rest of APAC)
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
• North America (U.S. and Canada)
• Latin America
• RoW

For each of the aforementioned regions and countries, detailed analysis and data about annual revenue of healthcare exoskeletons are available for every single year over 2014-2023.

The report also includes global annual shipment 2014-2023 based on direct sales, the split of global revenue by revenue mode over the forecast years, average selling price of healthcare exoskeletons for 2014-2023, current competitive scenario and the predicted manufacture trend, and profiles 12 healthcare exoskeleton vendors including market leaders and important emerging players.

Highlighted with 22 tables and 68 figures, this 141-page report provides timely data and detailed analysis to help clients targeting the global market to identify business opportunities and benchmark effective strategies.

Spanning over 141 pages, 22 Tables and 68 Figures “Global Healthcare Exoskeletons Market 2016-2023: Structure Analysis, Trend Outlook and Business Strategy” report covers Introduction, Market Overview and Qualitative Analysis, Segmentation of Global Market by Application, Segmentation of Global Market by Mobility Type, Segmentation of Global Market by Product Function, Segmentation of Global Market by Power Technology, Segmentation of Global Market by Region, Competitive Landscape. This report Covered 12 Companies - AlterG, Inc., Bionik Laboratories Corp., Cyberdyne, Inc., Ekso Bionics, Hocoma, Honda Motor Co., Ltd., Myomo, Panasonic Corporation (Activelink), Parker Hannifin Corporation, ReWalk Robotics Ltd., Rex Bionics Plc., U.S. Bionics, Inc. (suitX).

For more information Visit at: http://mrr.cm/3C5

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Biosimilar Market by Classes Industry Outlook 2020; New Report Launched

With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020” provides an in-depth analysis of global biosimilars market focusing on key segments detailing approved and upcoming biosimilar products. Market outlook for aforementioned biosimilar classes has been provided for the period 2017-20.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-

Market Segmentation by Classes

• Insulin
• Erythropoietin (EPO)
• Human Growth Hormone (HGH)
• Granulocyte- Colony Stimulating Factor (G-CSF)
• Monoclonal Antibody (mAb)
• Interferon (IFN)

Market Segmentation by Geography

• Developed Markets – Europe and the US
• Emerging Markets – China & India

Key Vendors

• Sandoz
• Hospira
• TEVA
• Celltrion
• Biocad
• Dong-A Pharmaceutical Co., Ltd.
• Stada

Spanning over 112 pages, 36 Tables and 48 Figures “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020” report covers Executive Summary, Research Methodology, Introduction, Global Biologics Market, Global Biosimilars Market, Global Biosimilars Market Segmentation, Global Biosimilars Market Analysis – Developed & Emerging Nations, Global Biosimilars – Pricing Analysis, Global Biosimilar Industry – SWOT Analysis, Global Biosimilars Market Attractiveness Index, Global Biosimilars Market Dynamics, Competitive Landscape, Company Profiles. This report Covered Companies - Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd.

For more information Visit at: http://mrr.cm/3Cc

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare